P
BOLT icon

Pfizer’s Bolt Biotherapeutics BOLT Stock Holding History

Pfizer’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134K Hold
31,305
– – 0.08% 14
2026
Q1 		$137K Hold
31,305
– – 0.06% 16
2025
Q4 		$171K Hold
31,305
– – 0.07% 16
2025
Q3 		$167K Hold
31,305
– – 0.04% 19
2025
Q2 		$181K Hold
31,305
– – 0.03% 19
2025
Q1 		$250K Hold
31,305
– – 0.05% 19
2024
Q4 		$335K Buy
+31,305
New +$378K 0.01% 21

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

Pfizer's BOLT Position: Q2 2026 in Review

Pfizer held its Bolt Biotherapeutics (BOLT) position steady in Q2 2026 at 31,305 shares worth $134K. The position accounts for 0.08% of the portfolio, ranked #14.

Pfizer first reported a position in BOLT in Q4 2024 and has held it in 7 quarters since. The position peaked at $335K in Q4 2024. 23 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • Pfizer held 31,305 shares of Bolt Biotherapeutics worth $134K as of Q2 2026.
  • Pfizer left its Bolt Biotherapeutics share count unchanged in Q2 2026.
  • Bolt Biotherapeutics made up 0.08% of Pfizer's portfolio in Q2 2026, its #14 holding.
  • Pfizer first reported a position in Bolt Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • Pfizer's Bolt Biotherapeutics position peaked at $335K in Q4 2024.
  • 23 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on Pfizer's 13F filing for Q2 2026, filed 13 Aug 2026.